Kidney Cancer

March is kidney cancer awareness month. Kidney cancer is the 7th most common cancer diagnosed
in the United States with more than new 81,000 cases each year.
The #AACRGENIE 17.0 public release provides a detailed look at the genomic landscape of Kidney
Cancer, offering valuable insights. The registry includes 3,174 patients and 3,379 samples, helping to
deepen our understanding of this cancer. VHL, PBRM1, SETD2, and BAP1 are the most frequently
mutated genes among other key mutations.
AACRGENIE, celebrating a decade of collaboration and powering the future of precision oncology.
Explore the data on cBioPortal.

Colorectal

March is Colorectal awareness month. As highlighted in a recent blog post, new advances are being made in the use of vaccines for treatment of this disease.​
​
The #AACRGENIE 17.0 public release provides a detailed look at the genomic landscape of colorectal cancer, offering valuable insights. The registry includes 19,544 patients and 20,599 samples, helping to deepen our understanding of this cancer. TP53, APC, KRAS and PIK3CA are the most frequently mutated genes among other key mutations. ​
​
These data highlight several clinically actionable alterations, including BRAF V600E and KRAS G12C mutations, ERBB2 amplification, as well as NTRK1, NTRK2, NTRK3, and RET fusions.

In addition, the #AACRGENIE BioPharma Collaborative (BPC) Colorectal 2.0-public cohort contains deep clinical annotation on 1,485 patients and 1,551 samples from the main GENIE registry.​
​
The BPC CRC 2.0-public release includes genomic data (NGS, 2014–2018), treatment histories (systemic therapies with timing intervals), and real-world outcomes via PRISSMM™. It captures pathology, imaging, and medical oncology evaluations to assess disease status and progression-free survival. Additional biomarkers (e.g., PDL1, MSI, MMR) are also included. More details can be found on the BPC CRC 2.0-public webpage and with dataset overview documentation.​
​
#AACRGENIE, celebrating a decade of collaboration and powering the future of precision oncology. ​
​
Explore the GENIE colorectal data on cBioPortal:​
cBioPortal CRC 17.0-public​
cBioPortal BPC CRC 2.0-public

Multiple MyelomA

March is Multiple Myeloma awareness month. Multiple Myeloma is a cancer of plasma cells found within the bone marrow. Each year, approximately 36,000 new cases are diagnosed in the United States. As discussed in a recent blog post, ongoing advancements in treatment and research are leading to improved patient outcomes, with innovative therapies like CAR T-cell treatments and bispecific engagers offering more personalized and effective regimens.​
​
The #AACRGENIE 17.0 public release provides a detailed look at the genomic landscape of Multiple Myeloma, offering valuable insights. The registry includes 1,167 patients and 1,548 samples, helping to deepen our understanding of this cancer. KRAS, TP53, NRAS, and DNMT3A are the most frequently mutated genes among other key mutations. The data below highlight several guideline recognized alterations, including the TP53 deletions as well as FGFR3 and NSD2 fusions. ​
​
#AACRGENIE, celebrating a decade of collaboration and powering the future of precision oncology. ​

Explore the Multiple Myeloma data on cBioPortal.

Gall Bladder

February is gallbladder and bile duct cancer awareness month. As highlighted in a recent blogpost, new advances are being made in the treatment of these rare diseases. The #AACRGENIE 17.0 public release provides a detailed look at the genomic landscape of gallbladder and bile duct cancers, offering valuable insights. The registry includes 4,416 patients and 4,625 samples, helping to deepen our understanding of these rare cancers. TP53, KRAS, IDH1, CTNNB1, and SMAD4 are the most frequently mutated genes among other key mutations.

The data below highlight several clinically actionable alterations, including the BRAF V600E mutation and fusions in NTRK1, NTRK2, NTRK3, and RET.

You can explore Project GENIE’s hepatobiliary data at genie.cbioportal.org.